By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm Med BioGene today reported that its first-quarter net loss increased around 6 percent as it continued to prepare to launch its LungExpress Dx test.

The Vancouver, BC-based firm reported no revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.